Weekly roundup: Success for Optimum clients in and out of the clinic
Poolbeg granted FDA Orphan Drug Designation for POLB 001
Poolbeg announced that the US Food and Drug Administration had granted Orphan Drug Designation to POLB 001 as an oral preventative therapy for T-cell engager bispecific antibody-induced Cytokine Release Syndrome.
Nucleome Therapeutics appoints Bhavna Hunjan as Chief Business Officer
Nucleome Therapeutics, a biotechnology company harnessing the power of non-coding human genetics to discover first-in-class antibody treatments for inflammatory diseases, announced that it has appointed Bhavna Hunjan as Chief Business Officer with immediate effect.
STORM Therapeutics announced that the first patient had been dosed in clinical collaboration to evaluate STC-15 in combination with LOQTORZI® and the appointment of Atif Abbas, M.D., as Chief Medical Officer
STORM Therapeutics announced the dosing of its first patient in a collaboration with Coherus BioSciences, Inc. and a Phase 1b/2 study evaluating STC-15, its first-in-class lead program, in combination with LOQTORZI (toripalimab-tpzi), the anti-PD-1 antibody, for the treatment of non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), melanoma and endometrial cancer. It also announced the appointment of Atif Abbas, M.D. as Chief Medical Officer.
Bionical Emas and Pharma Resources announce exclusive global clinical trial supply partnership
Bionical Emas announced an exclusive global clinical trial supply agreement with Pharma Resources GmbH, the German pharmaceutical company and marketing authorization holder. This strategic partnership marks Pharma Resources’ entry into the clinical trial supply market and grants Bionical Emas exclusive rights to distribute its key EU-marketed oncology injectables, including Fluorouracil, which is currently in critical shortage across Europe.
Heidelberg Pharma announces first patient dosed in Phase I Study of Amanitin-based ADC candidate HDP-102 for Non-Hodgkin Lymphoma
Heidelberg Pharma a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), announced that the first patient has been dosed in a Phase I clinical study evaluating HDP-102 for the treatment of non-Hodgkin lymphoma (NHL).
🔥Hot topic
👥Industry events
Optimum’s 17th Annual Healthcare Conference
It is now less than five months until Optimum’s 17th Annual Healthcare Conference 2025! Returning to the King’s Fund this autumn, this prestigious invitation-only event brings together investors and executives from across the life sciences sector, register your interest today.
That’s all folks! To stay in the know – subscribe to Optimum’s weekly wrap-up today!
